Outlook Therapeutics, Inc.: Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA

Outlook Therapeutics (OTLK) shares fell about 24% to $0.84 after the company priced a public offering of 55.56 million shares plus warrants for gross proceeds of about $55 million. Shares and warrants were priced at $0.99 each; warrants are exercisable at $1.10 for five years. Proceeds will fund the U.S. launch of LYTENAVA and general corporate needs.

Outlook Therapeutics (OTLK) shares fell about 25.6% in pre-open after the company priced an underwritten public offering of about 55.6M shares plus an equal number of warrants, raising about $55M at $0.99 per share and warrant, below the prior close. Net proceeds will fund the U.S. launch of LYTENAVA and general corporate uses. An 8/14 earnings report is upcoming.

Outlook Therapeutics, Inc. (OTLK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622278d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Risk Factors You should consider carefully the risks and uncertainties described below. If any of the following risks are realized, our business, financial condition, results of operations, and prospects could be adversel

The healthcare sector saw multiple company-specific moves. Pfizer and BioNTech received EU approval for an updated COVID-19 vaccine targeting the XFG variant. Cipla won FDA approval for generic Advair Diskus, and Viatris gained FDA approval for its Gwyn Lo contraceptive patch. AbbVie’s Rinvoq was approved in the EU for non-segmental vitiligo. Boston Scientific announced an $800M restructuring plan, while GSK launched a $2.5B cost-saving program. J&J and Sail agreed a $3.51B CAR-T deal; Argenx ac

The U.S. retina care market continues to draw attention from life sciences investors as new treatments address wet age-related macular degeneration, a leading cause of vision loss in older adults. Outlook Therapeutics Inc. (OTLK:NASDAQ) now stands at the center of this opportunity after securing regulatory clearance for its lead candidate. Market Opportunity in Retina Care Wet age-related macular degeneration damages central vision through abnormal blood vessel growth under the retina.

Outlook Therapeutics said the FDA approved LYTENAVA, an ophthalmic bevacizumab formulation for wet AMD, after three prior FDA rejections. The company expects 12 years of reference product exclusivity and plans a commercial rollout, with eligible patients expected to access it before year-end. Outlook Therapeutics shares were down 9.60% to $1.27.